These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32638146)

  • 1. CcpNmr AnalysisScreen, a new software programme with dedicated automated analysis tools for fragment-based drug discovery by NMR.
    Mureddu LG; Ragan TJ; Brooksbank EJ; Vuister GW
    J Biomol NMR; 2020 Nov; 74(10-11):565-577. PubMed ID: 32638146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CcpNmr AnalysisAssign: a flexible platform for integrated NMR analysis.
    Skinner SP; Fogh RH; Boucher W; Ragan TJ; Mureddu LG; Vuister GW
    J Biomol NMR; 2016 Oct; 66(2):111-124. PubMed ID: 27663422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficiently driving protein-based fragment screening and lead discovery using two-dimensional NMR.
    Peng C; Namanja AT; Munoz E; Wu H; Frederick TE; Maestre-Martinez M; Iglesias Fernandez I; Sun Q; Cobas C; Sun C; Petros AM
    J Biomol NMR; 2023 Apr; 77(1-2):39-53. PubMed ID: 36512150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMR-based fragment screening and lead discovery accelerated by principal component analysis.
    Namanja AT; Xu J; Wu H; Sun Q; Upadhyay AK; Sun C; Van Doren SR; Petros AM
    J Biomol NMR; 2019 Dec; 73(12):675-685. PubMed ID: 31541395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMR quality control of fragment libraries for screening.
    Sreeramulu S; Richter C; Kuehn T; Azzaoui K; Blommers MJJ; Del Conte R; Fragai M; Trieloff N; Schmieder P; Nazaré M; Specker E; Ivanov V; Oschkinat H; Banci L; Schwalbe H
    J Biomol NMR; 2020 Nov; 74(10-11):555-563. PubMed ID: 32533387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of Solution NMR in Drug Discovery.
    Shi L; Zhang N
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AutoDrug: fully automated macromolecular crystallography workflows for fragment-based drug discovery.
    Tsai Y; McPhillips SE; González A; McPhillips TM; Zinn D; Cohen AE; Feese MD; Bushnell D; Tiefenbrunn T; Stout CD; Ludaescher B; Hedman B; Hodgson KO; Soltis SM
    Acta Crystallogr D Biol Crystallogr; 2013 May; 69(Pt 5):796-803. PubMed ID: 23633588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Straightforward and complete deposition of NMR data to the PDBe.
    Penkett CJ; van Ginkel G; Velankar S; Swaminathan J; Ulrich EL; Mading S; Stevens TJ; Fogh RH; Gutmanas A; Kleywegt GJ; Henrick K; Vranken WF
    J Biomol NMR; 2010 Oct; 48(2):85-92. PubMed ID: 20680401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR spectroscopy: the swiss army knife of drug discovery.
    Horst R; Farley KA; Kormos BL; Withka JM
    J Biomol NMR; 2020 Nov; 74(10-11):509-519. PubMed ID: 32617727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Kinase Production and Fragment Screening by NMR Spectroscopy.
    Han B; Ahn HC
    Methods Mol Biol; 2016; 1360():35-46. PubMed ID: 26501900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive automation for NMR structure determination of proteins.
    Guerry P; Herrmann T
    Methods Mol Biol; 2012; 831():429-51. PubMed ID: 22167686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting biomolecular NMR spectroscopy for promoting small-molecule drug discovery.
    Hanzawa H; Shimada T; Takahashi M; Takahashi H
    J Biomol NMR; 2020 Nov; 74(10-11):501-508. PubMed ID: 32306215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
    Hoffer L; Renaud JP; Horvath D
    J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-based screening by protein-detected NMR spectroscopy.
    Kerber PJ; Nuñez R; Jensen DR; Zhou AL; Peterson FC; Hill RB; Volkman BF; Smith BC
    Methods Enzymol; 2023; 690():285-310. PubMed ID: 37858532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-Based Drug Discovery by NMR. Where Are the Successes and Where can It Be Improved?
    Mureddu LG; Vuister GW
    Front Mol Biosci; 2022; 9():834453. PubMed ID: 35252355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective progression of nuclear magnetic resonance-detected fragment hits.
    Eaton HL; Wyss DF
    Methods Enzymol; 2011; 493():447-68. PubMed ID: 21371601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMR-Fragment Based Virtual Screening: A Brief Overview.
    Singh M; Tam B; Akabayov B
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29370102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.